Flinn

Flinn, a pan-European AI-powered regulatory and quality automation software company for medtech and pharma, has secured an additional $20 million in funding to enhance automation throughout the medical and pharmaceutical product lifecycle. The funding round was led by HV Capital, with participation from US-based BHI – Bertelsmann Healthcare Investments, along with continued support from Cherry Ventures, Speedinvest, and SquareOne.

Vienna-based Flinn, an AI-powered software provider, has secured $20 million in follow-on funding to automate regulatory and quality processes in medtech. The funding round was led by HV Capital, with participation from Bertelsmann Healthcare Investments and continued support from Cherry Ventures, Speedinvest, and SquareOne. Flinn's software addresses challenges in healthcare by replacing manual workflows with scalable solutions, enhancing operational efficiency and compliance for medtech manufacturers. The new capital will help extend its platform and support international growth, particularly in Europe and the US.